B7-H3 CAR-T for Recurrent or Refractory Glioblastoma
B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Sponsor: BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.
Listed as NCT04077866, this PHASE1/PHASE2 trial focuses on Recurrent Glioblastoma and Refractory Glioblastoma and remains ongoing. Sponsored by BoYuan RunSheng Pharma (Hangzhou) Co., Ltd., it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.
- Huizhou Municipal Central Hospital
- Ningbo Yinzhou People's Hospital
- Second Affiliated Hospital, School of Medicine, Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .